Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29976743 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDM4EHDAC4HDAC3 | |
| SCHEMBL29977498 | 0.89 | KDM4E (0.55) | MEN1KMT2AKDM4EHDAC4HDAC3 | |
| SCHEMBL2064097 | 0.88 | PTGER3 (0.50) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL29650191 | 0.88 | PTGER3 (0.50) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL14364236 | 0.86 | TSHR (0.57) | MEN1KMT2AKDM4EHDAC4HDAC3 | |
| SCHEMBL1022827 | 0.86 | PTGER3 (0.49) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL3238435 | 0.85 | PTGER3 (0.49) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL18184674 | 0.85 | ATM (0.63) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL14881901 | 0.84 | PTGER3 (0.55) | MEN1KMT2AHDAC4HDAC3HDAC1 | |
| SCHEMBL3732675 | 0.84 | CYP2C9 (0.54) | MEN1KMT2AKDM4EHDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | MEN1 3422/4885KMT2A 3822/4885KDM4E 2338/4885 |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | MEN1 3073/4885KMT2A 1825/4885KDM4E 1495/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | MEN1 593/4885KMT2A 1259/4885KDM4E 911/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | MEN1 593/4885KMT2A 1259/4885KDM4E 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.